<DOC>
	<DOCNO>NCT03085966</DOCNO>
	<brief_summary>Study autologous immune cell therapy combination luteinizing hormone release hormone agonist ( LHRH-a ) patient metastatic castration-resistant prostate cancer</brief_summary>
	<brief_title>Autologous Immune Cell Therapy Combination With LHRH-a Patients With mCRPC</brief_title>
	<detailed_description>Autologous dendritic cell ( DC ) know activate immune cell , central memory T cell ( Tcm cell ) , able mount attack cancer cell . The purpose study evaluate feasibility , safety efficacy patient ' immune cell combine luteinizing hormone release hormone agonist ( LHRH-a ) treatment metastatic castration-resistant prostate cancer .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
	<criteria>Males age ≥ 18 years； Subjects understand sign consent form study； Metastatic， castrate resistant , histologically confirm prostate cancer； PSA &gt; 5ng / ml； Serum testosterone ≤ 17nmol / L ( 50ng / dl ) ； Expected survival time least 24 months； Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1； Subjects receive chemotherapy , radiation therapy , surgery treatment within 4 weeks； The subject allergic history medicine food； The patient serious heart disease , include limited myocardial infarction , cardiomyopathy , valvular disease , malignant arrhythmia； Hb &lt; 9.0 g / 100ml , WBC &lt; 3 ×10^9/ L , LY &lt; 1.0 x10^9/ L , platelet &lt; 100,000 / mm3； Patients immune disease autoimmune disease ( Multiple sclerosis , systemic lupus erythematosus，rheumatoid arthritis inflammatory bowel disease , vitiligo ) ； The subject uncontrolled hardtocontrol disease liver , kidney system； Patient visceral metastasis , pathological fracture , spinal cord compression symptoms； Severe pain associate bone metastasis ( VAS score ≧ 4 point ) ； Patient receive immunotherapy ( include limit PD1 / PDL1 , etc . ) ； patient irregular hemorrhagic disease； Subject HIV , hepatitis B virus , hepatitis C virus , Treponema pallidum infection； Subject uncontrollable seizure , mental loss selfknowledge on； The subject history malignant tumor； The patient drug abuse , drug abuse , long history alcoholism 12 year prior trial； The subject participate clinical trial 3 month prior trial； The subject unsuitable adverse condition determine investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>central memory T cell</keyword>
	<keyword>metastatic castration-resistant prostate cancer</keyword>
</DOC>